Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29495930 | 1.00 | AKR1C3 (0.51) | AKR1C3AKR1C2ALDH1A1KMT2AMEN1 | |
| SCHEMBL1169066 | 0.82 | AKR1C3 (0.72) | AKR1C3AKR1C2PTGS1PTGS2TAS2R14 | |
| SCHEMBL22628424 | 0.80 | AKR1C3 (0.44) | AKR1C3AKR1C2NPC1RAB9APTGS1 | |
| SCHEMBL477610 | 0.80 | AKR1C3 (0.51) | AKR1C3AKR1C2ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL28967024 | 0.79 | AKR1C3 (0.47) | AKR1C3AKR1C2ALDH1A1KMT2AMEN1 | |
| SCHEMBL20560610 | 0.78 | AKR1C3 (0.50) | AKR1C3AKR1C2KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL279656 | 0.78 | ALDH1A1 (0.59) | ALDH1A1KMT2AMEN1SMN1; SMN2MAPK1 | |
| SCHEMBL1194372 | 0.76 | GSK3B (0.52) | AKR1C3AKR1C2PTGS1PTGS2TAS2R14 | |
| SCHEMBL1633802 | 0.76 | ALDH1A1 (0.58) | AKR1C3AKR1C2ALDH1A1KMT2AMEN1 | |
| SCHEMBL30782680 | 0.76 | ALDH1A1 (0.58) | AKR1C3AKR1C2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4570800-A1 | CRYSTAL FORM OF PYRIDINOPYRIMIDINONE COMPOUND, ACID SALT THEREOF, CRYSTAL FORM OF ACID SALT THEREOF, AND USE | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-06-18 | — | — | EP | disclosed |
| US-20240166645-A1 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2024-05-23 | — | — | US | disclosed |
| CN-117534667-A | Crystal forms of pyridopyrimidinone compound, acid salts thereof, crystal forms of acid salts thereof and use | 武汉人福创新药物研发中心有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117357650-A | Pharmaceutical composition comprising SOS1 inhibitor | 武汉人福创新药物研发中心有限公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4289843-A1 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289843-A1 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4272836-A2 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023150291-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023022497-A1 | SOS1 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-02-23 | — | — | WO | disclosed |
| CN-114907341-A | Pyridopyrimidinone derivatives, and preparation method and application thereof | 武汉人福创新药物研发中心有限公司 | 2022-08-16 | — | — | CN | disclosed |
| WO-2022166974-A1 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-08-11 | — | — | WO | disclosed |
| WO-2022148442-A1 | 6-SUBSTITUTED PHOSPHORYL QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-07-14 | — | — | WO | disclosed |
| WO-2022148442-A1 | 6-SUBSTITUTED PHOSPHORYL QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-07-14 | — | — | WO | disclosed |
| CN-114716478-A | 6-substituted phosphoryl quinazoline derivative and preparation method and application thereof | 武汉人福创新药物研发中心有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2020221209-A1 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2020-11-05 | — | — | WO | disclosed |
| US-8466169-B2 | SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-7863269-B2 | protease-activated receptor 1 (PAR1) inhibitors such as 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3-iminoimidazo[1,5-a]pyridin-2-yl)ethanone, used as anticoagulants | SANOFI-AVENTIS (FR) | 2011-01-04 | — | — | US | disclosed |
| US-20090192150-A1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166645-A1 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SOS1, WEE1, SOS2 | AKR1C3 1020/4885AKR1C2 466/4885ALDH1A1 1043/4885 |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | APC, RCC2, CDC37 | AKR1C3 1858/4885AKR1C2 1947/4885ALDH1A1 2243/4885 |
| US-20090192150-A1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | F2R, TFPI, F2RL1 | AKR1C3 1437/4885AKR1C2 2308/4885ALDH1A1 504/4885 |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL1, F2RL3 | AKR1C3 924/4885AKR1C2 2356/4885ALDH1A1 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.